PAR · GNFT.PA
Genfit S.A.
€11.40-€0.06 (-0.52%)
Genfit S.A.’s quoted price sits in the upper half of its reported 52-week range, 26.36% below the high.
Loading market information…
PAR · ALSEN.PA · EUR
Stock price, earnings
Quote as of Oct 29, 2026, 04:35 PM UTC. Cached market data; not a live quote.
One-year closing-price history · EUR. Historical prices are not a forecast.
Sensorion S.A.’s quoted price sits in the lower half of its reported 52-week range, 77.97% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Sensorion S.A.’s next earnings report is currently expected on Mar 18, 2027, with estimated earnings per share of -€2.01. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Sensorion S.A.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Sensorion SA is a clinical-stage biopharmaceutical firm based in Montpellier, France, specializing in the development of therapies for inner ear disorders. Their key initiatives include gene therapy programs: OTOF-GT, designed to restore hearing for individuals with Otoferlin deficiency, and USHER-T1-GT, targeting Usher syndrome Type 1. The company also advances SENS-401, a drug candidate for treating sudden sensorineural hearing loss. Sensorion's broader pipeline encompasses numerous experimental treatments aimed at restoring, treating, and preventing various conditions affecting the inner ear. They hold a collaboration agreement with Institut Pasteur concerning gene therapy for both pediatric and adult deafness. Additionally, Sensorion partners with Sonova Holding AG to integrate genetic analysis into the routine diagnosis of progressive adult hearing loss, combining advanced therapeutic approaches with traditional hearing aids. Founded in 2009, Sensorion SA operates primarily in France.
Latest available per-share figures in EUR. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 06:31 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q4 2023 |
|---|
| Mar 14, 2024 |
| -€0.05+98.75% vs estimate |
| €3.08M+13.47% vs estimate |
| Q2 2023 | Sep 20, 2023 | -€0.15+100.0% vs estimate | €2.65M |
|---|
| Q4 2022 | Jun 7, 2023 | -€7.00-6,263.64% vs estimate | €3.04M+44.85% vs estimate |
|---|
KEEP COMPARING
€11.40-€0.06 (-0.52%)
Genfit S.A.’s quoted price sits in the upper half of its reported 52-week range, 26.36% below the high.
€4.26-€0.12 (-2.63%)
Median Technologies S.A.’s quoted price sits in the lower half of its reported 52-week range, 41.47% below the high.
€0.72-€0.01 (-1.63%)
Transgene S.A.’s quoted price sits in the lower half of its reported 52-week range, 51.8% below the high.
€1.29+€0.01 (+0.63%)
Innate Pharma S.A.’s quoted price sits in the lower half of its reported 52-week range, 44.81% below the high.
€1.27+€0.02 (+1.59%)
Crossject S.A.’s quoted price sits in the lower half of its reported 52-week range, 52.81% below the high.
€1.69+€0.02 (+1.07%)
ABIONYX Pharma S.A.’s quoted price sits in the lower half of its reported 52-week range, 63.17% below the high.
€3.06-€0.06 (-1.99%)
Adocia S.A.’s quoted price sits in the lower half of its reported 52-week range, 68.29% below the high.
€2.11-€0.08 (-3.84%)
OSE Immunotherapeutics S.A.’s quoted price sits in the lower half of its reported 52-week range, 65.48% below the high.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
